• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

    2/9/23 11:27:44 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NBIX alert in real time by email
    SC 13G/A 1 tv01504-neurocrinebioscience.htm SCHEDULE 13G/A neurocrinebiosciencesinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 7)*

    Name of issuer:  Neurocrine Biosciences Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  64125C109

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  64125C109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    63,062

    7.  SOLE DISPOSITIVE POWER

    9,205,297

    8.  SHARED DISPOSITIVE POWER

    134,998

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,340,295

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.72%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Neurocrine Biosciences Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    12780 El Camino Real
    San Diego, CA 92130

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    64125C109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $NBIX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NBIX

    DatePrice TargetRatingAnalyst
    4/15/2025$138.00Hold → Buy
    Needham
    4/14/2025$137.00Sector Perform → Outperform
    RBC Capital Mkts
    2/11/2025$138.00Hold
    Deutsche Bank
    10/10/2024$155.00Outperform
    Raymond James
    8/29/2024$131.00 → $159.00Neutral → Overweight
    Piper Sandler
    4/24/2024$140.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    12/13/2023$127.00Neutral
    Citigroup
    12/12/2023$136.00Buy
    Deutsche Bank
    More analyst ratings

    $NBIX
    SEC Filings

    See more
    • Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/30/25 4:05:10 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/22/25 4:03:59 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Neurocrine Biosciences Inc.

      S-8 POS - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/21/25 5:28:04 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist

      SAN DIEGO, June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants. NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia (CAH). "As a leader in CAH, Neurocrine is dedicated to expanding treatment

      6/30/25 4:05:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

      Patient-reported analyses demonstrated greater reduction in both cognitive and motor-related disease burden for INGREZZA compared with placeboFindings to be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders (ATMRD) CongressSAN DIEGO, June 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced new patient-reported post-hoc data from the KINECT®-HD study highlighting significant reductions in both cognitive and motor-related burdens among adults treated for Huntington's disease chorea with once-daily INGREZZA® (valbenazine) capsules. KINECT-HD is the first and only clinical study to demonstrate measurable changes in cognitive and motor dis

      6/27/25 8:30:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia

      Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at the 2025 American Association of Nurse Practitioners (AANP) National Conference SAN DIEGO, June 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study demonstrating significant patient-reported improvements in health-related quality of life and functional measures among adults aged 65 years and older with tardive dyskinesia who received continued treatment with INGREZZA® (valbenazine) capsules. Findings will be prese

      6/20/25 8:30:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Neurocrine Biosciences upgraded by Needham with a new price target

      Needham upgraded Neurocrine Biosciences from Hold to Buy and set a new price target of $138.00

      4/15/25 7:52:35 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Neurocrine Biosciences from Sector Perform to Outperform and set a new price target of $137.00

      4/14/25 8:05:29 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Neurocrine Biosciences with a new price target

      Deutsche Bank initiated coverage of Neurocrine Biosciences with a rating of Hold and set a new price target of $138.00

      2/11/25 7:09:50 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

      For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con

      12/13/24 5:54:17 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Keswani Sanjay Chandru

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      6/4/25 5:37:41 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Keswani Sanjay Chandru

      3 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      6/4/25 5:34:40 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Gorman Kevin Charles sold $1,157,211 worth of shares (9,613 units at $120.38), decreasing direct ownership by 2% to 514,596 units (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      5/29/25 6:15:13 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

      SAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. "Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change," said Matt Abernethy, Chief Finan

      6/9/25 4:05:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

      SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

      5/30/25 4:30:14 PM ET
      $FATE
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

      Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an accomplished physician-scientist who has more than 20 years of pharmaceutical industry experience with broad R&D expertise in multiple therapeutic areas, will lead the clinical development and medical affairs activities at Neurocrine. Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as C

      4/4/25 8:00:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Financials

    Live finance-specific insights

    See more
    • Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

      INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms Initiated Phase 3 Registrational Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia to Position for Next Phase of Growth SAN DIEGO, May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial guidance.

      5/5/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results

      Conference Call and Webcast Scheduled for Monday, May 5 SAN DIEGO, April 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its first quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2025. The schedule for the press release and conference call / webcast is as follows: Q1 2025 Press Release: May 5, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ1 2025 Conference Call: May 5, 2025 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-245-3047International Dial

      4/14/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

      INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont), a First-in-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia, Approved and Launched in the United States Phase 3 Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia Initiating in the First Half of 2025 SAN DIEGO, Feb. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the fourth quart

      2/6/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Neurocrine Biosciences Inc.

      SC 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      10/17/24 9:54:01 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

      SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      2/9/23 11:27:44 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

      SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      2/14/22 2:34:19 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care